{Reference Type}: Journal Article
{Title}: Harnessing cGAS-STING axis for therapeutic benefits in systemic lupus erythematosus.
{Author}: Chang L;
{Journal}: Int J Rheum Dis
{Volume}: 27
{Issue}: 7
{Year}: 2024 Jul
{Factor}: 2.558
{DOI}: 10.1111/1756-185X.15256
{Abstract}: The cyclic GMP-AMP synthase (cGAS), a prominent intracellular DNA sensor in mammalian cells, controls the innate immune response and the stimulator of interferon genes (STING)-mediated synthesis of pro-inflammatory cytokines, such as type-I interferon (IFN-I). For decades, IFN-I has been hypothesized to be essential in the development of systemic lupus erythematosus (SLE), a chronic multisystem autoimmunity characterized by immune complex (IC) deposition in small vessels. Recent findings revealed that the activation of the cGAS-STING pathway by self-DNA would propagate the autoimmune responses via upregulating IFN-I production in SLE. In this review, we aimed to provide a comprehensive outlook of the role of the cGAS-STING pathway in SLE pathobiology, as well as, a better understanding of current therapeutic opportunities targeting this axis.